
|Videos|October 7, 2020
Using the New Indication for Esketamine to Treat Patients with Major Depressive Disorder
Author(s)Gerard Sanacora, MD, PhD
Dr Sanacora discusses the new indication for esketamine, SPRAVATO®, and how it might be used to treat patients with Major Depressive Disorder with acute risk of suicide ideation.
Advertisement
Dr Sanacora is a Professor of Psychiatry at Yale University, Director of the Yale Depression Research Program, and Co-Director of the Yale New Haven Hospital Interventional Psychiatry Service.
Newsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Psychiatric Times
1
ADHD Found Connected to Substance Use Disorder, With Sex Prevalence Differences
2
Sleep as Connective Tissue: Quantifying Team Dynamics in Elite Sports
3
Lithium-Loaded Gold Nanoparticle Nasal Spray to Treat Neuropsychiatric Diseases
4
A Moral Injury Update: The PNHP Study and an Imminent Step Toward Peace in the Mideast
5